InnovationMap · Jul 2026
Local coverage of the Series A and TYBR's B3 GEL commercialization plans, including comments on the product's fit with existing surgical workflows.
Natural hydrogel to keep internal organs scar-free after surgery
Company research
Public company, workplace, funding, and market signals
Overview
Houston-based medical technology / regenerative medicine startup developing the B3 GEL™ System, a flowable ECM hydrogel used to protect healing soft tissues after surgery and reduce post-surgical tethering/scar formation.
Primary product
B3 GEL™ System
Founded
2020
Headquarters
Houston, Texas, United States
Team size
1-10 employees
Work style
Onsite
Industry
Medical Equipment Manufacturing
Sub-industry
Medical technology / regenerative medicine
Offices
2450 Holcombe Blvd Suite X, Houston, TX 77021, United States (HQ)
Houston, Texas, United States
Business model
B2B hardware sales
medical device sales
surgical product commercialization
Funding
Stage
Series A
Total raised
$39.5M
Latest round
Series A · Jul 2026
Latest amount
$30M
People & investors
Leadership
Co-founder / CEO
CTO & Co-founder
Chief Commercial Officer
Board Member
Chairman of the Board of Directors
Vice President of Quality
Independent Director / Board Member
Founders
Co-founder / Advisor
Work & culture
Mission-driven medtech startup focused on evidence generation, surgeon workflow fit, and improved post-operative mobility outcomes; public posts emphasize teamwork, clinical validation, and commercialization.
Work style
Onsite
Product & market
Pricing
Not publicly disclosed; appears to be sold as a B2B surgical device / procedure-adjunct product.
Differentiators
- —flowable gel that conforms to complex anatomy
- —blue color enables visual confirmation of placement
- —thermally responsive and resorbable over time
- —designed to preserve tendon/ligament glide during healing
- —integrates into existing surgical workflows with a proprietary applicator
- —aimed at reducing revision costs and extended rehabilitation
Technology
extracellular matrix (ECM) hydrogel
decellularized extracellular matrix
collagen-based bio-gel
thermally responsive flowable gel
proprietary mixer-applicator delivery system
FDA-cleared soft-tissue protection platform
Customers
orthopedic surgeons
hand and wrist surgeons
sports medicine surgeons
health systems
hospitals
Competitors
sheet-based adhesion barriers
other anti-adhesion surgical barriers
adjacent soft-tissue recovery adjuncts
Scale & contact
Latest news
PRNewswire · Jul 2026
Announced a $30 million Series A led by Vensana Capital and Mutual Capital Partners, with participation from Neovate Capital Partners and existing investors; funds will expand commercialization and clinical studies.
PRNewswire · Jan 2026
Reported first U.S. clinical cases using B3 GEL and described early real-world use in orthopedic soft-tissue procedures.
PRNewswire · Sep 2025
Announced first patient enrollment in an Australian clinical trial evaluating B3 GEL in tendon tenolysis procedures.
PRNewswire · Jun 2025
Announced FDA 510(k) clearance for the B3 GEL System and described the product as a bioresorbable flowable barrier for tendon, ligament, and muscle surgeries.
Jobs and careers at TYBR Health
0 jobs at TYBR Health
No open positions
Check back later for new openings